| Name | Title | Contact Details |
|---|
Aldevron provides contract manufacturing and scientific services. We specialize in plasmid DNA, protein production, and antibody generation. PLASMID DNA PRODUCTION With the successful completion of over 50,000 projects, we have developed unsurpassed expertise in plasmid manufacturing. Using proprietary technology, Aldevron manufactures DNA for a wide range of research, preclinical, clinical, and diagnostic applications (1 mg to 100 g). PROTEIN PRODUCTION Aldevron offers a wide range of protein services including host cell optimization, expression screening, process development, contract production, enzyme and antibody assay design, and more. Proteins produced by Aldevron are used for a wide range of agriculture and biomedical applications from research grade to full cGMP. ANTIBODY GENERATION GENOVAC Antibody Technology supports all project types from reagent antibodies to diagnostic and therapeutic applications with high success rates. Based on many years of experience, our immunization technology has been developed to cater for all protein targets where other methods have failed (including e.g. GPCRs). Our custom antibodies have been validated in over 130 publications and patents for more than 500 clients worldwide. Additional services include antibody processing, production, labeling, characterization and sequencing.
Canadian Bacterial Diseases Network (CBDN) is a Calgary, AB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to increase muscle function and contractility. Cytokinetics’ lead drug candidate is tirasemtiv, a fast skeletal muscle troponin activator, for the potential treatment of ALS. Tirasemtiv has been granted orphan drug designation and fast track status by the U.S. Food and Drug Administration and orphan medicinal product designation by the European Medicines Agency for the potential treatment of ALS. Cytokinetics retains the right to develop and commercialize tirasemtiv. Cytokinetics is collaborating with Amgen Inc. to develop omecamtiv mecarbil, a novel cardiac muscle activator, for the potential treatment of heart failure. Cytokinetics is collaborating with Astellas Pharma Inc. to develop CK-2127107, a fast skeletal muscle activator, for the potential treatment of spinal muscular atrophy and chronic obstructive pulmonary disease. Amgen holds an exclusive license worldwide to develop and commercialize omecamtiv mecarbil and Astellas holds an exclusive license worldwide to develop and commercialize CK-2127107. Both licenses are subject to Cytokinetics` specified development and commercialization participation rights.
Omnicia is a South San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Oral integrin therapies for patients with immunological, fibrotic, neoplastic and vascular diseases. Morphic Tx is joining a three decade quest led by our scientific founder, Tim Springer, who initially discovered the integrin receptor family in the 1980s. This receptor family is an important drug target that has fueled the successful development of six injectable therapies approved for treatment of multiple sclerosis, ulcerative colitis, Crohn`s disease, plaque psoriasis, acute coronary syndrome and complications during percutaneous coronary intervention.